I don't think that necessarily answers my question.
Do you have any sensitivity analysis or otherwise done that factors in higher spodumene prices, and how a lower production volume would affect overall EBITDA?
All Li shares are down across the board 20 - 25% from their all time highs, I don't think we can pin the SP purely on the quarterly announcement. To me this is more general market weakness than company specific performance.
Good News & Bad News, page-8217
-
- There are more pages in this discussion • 36,420 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.02 |
Change
0.145(5.05%) |
Mkt cap ! $9.060B | |||
| Open | High | Low | Value | Volume |
| $2.99 | $3.10 | $2.95 | $60.85M | 20.14M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 294135 | $3.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.02 | 281199 | 44 |
View Market Depth
| Last trade - 12.13pm 26/07/2024 (20 minute delay) ? |
| PLS (ASX) Chart |